1. Scrip
  2. >>New Products

BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval

 
• By Joseph Haas

The LAG-3 antibody relatlimab, with Opdivo in the fixed-dose combo Opdualag and a $27,389-per-dose price, is the first approved in a new class of checkpoint inhibitors since the anti-PD-1/PD-L1s.

New cancer discovery
Bristol gets first approval for new checkpoint immunotherapy, LAG-3 • Source: Alamy

US Food and Drug Administration approval of Bristol Myers Squibb Company’s third class of checkpoint inhibitor – the LAG-3 blocker relatlimab in a fixed-dose combination with Opdivo (nivolumab) for unresectable or metastatic melanoma – is a crucial win in the hyper-competitive immuno-oncology space.

The product, branded Opdualag, also offers BMS some protection against Opdivo’s US patent expiration in 2028, and while it could be a modest near-term blow to competitor Merck & Co., Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.